COMPANY PROFILE
Light & Bio is a technology company in the field of precision medicine, relying on single molecule detection and other precision detection technologies to provide products and solutions for the process of disease discovery, treatment and drug development. We are committed to detecting diseases earlier and intervening timely in diagnosis; monitoring precisely in treatment to improve efficacy; and detecting precisely in drug development to reduce cost. Our Chief Scientific Advisor, Professor Kim Dae Yong, hopes to provide the global pharmaceutical industry with a nanoscale precision detection platform using ultra-high brightness rare earth materials and advanced single-particle detection technology. In the March 2020 issue of Nature, he and Nobel Laureate Professor Steven Chu summarised and looked forward to the field. He believes that the nanoscale is the basic level of biomolecular functioning and the scale where diseases originate, and is committed to developing more convenient and accurate precision detection technologies for the benefit of human health.
NEWS CENTER
Dr Hao He, the founder of the company, studied under Professor Kim and returned to China in October 2019 to establish Light & Bio to convert the technology to industry. The company's mission is to empower precision medicine for the benefit of human health. The company's vision is to become the preferred provider of detection solutions in the field of precision medicine.
-
【喜讯】光与生物荣获肿瘤早筛领域“价值领域奖”
2023年5月6日,第七届未来医疗100强·个性化诊疗论坛成功召开,“价值领域奖”颁奖晚宴同期举行。
在个性化诊疗论坛上,创始人何皓博士与大咖们一起为行业发展提供新方向、新思路。2023-12-28
-
助力前列腺癌早检早筛 光与生物寻求创业合伙人
2023年5月28日,第二十届中国国际检验医学暨输血仪器试剂博览会(CACLP)在南昌绿地博览中心隆重开幕。
本次展会面积130000㎡,来自海内外20多个国家和地区体外诊断上、中、下游全产业链1300多家企业齐聚南昌,共同探讨行业发展趋势、前沿技术。2023-12-28
-
顶刊综述 | 光学单分子检测进展:迈向超灵敏生物亲和性测定
顶刊综述 | 光学单分子检测进展:迈向超灵敏生物亲和性测定
《ANGEW CHEM INT EDIT》杂志发表综述,阐述了光学单分子检测的理论背景,介绍了多种光学单分子标记技术,并选取多种用于检测蛋白或核酸的生物亲和性测定作为示例。本文对这篇综述作一简单的译文和解读。2023-12-27
Lab address:No. 10, Binlang Road, Futian bonded area, Fubao street, Futian District, Shenzhen , China
[WeChat Public]